Natural killer cell activity and anti-tumour effects of dehydrocrotonin and its synthetic derivatives

被引:10
|
作者
Melo, PS
Justo, GZ
Durán, N
Haun, M
机构
[1] Univ Estadual Campinas, Dept Bioquim, Inst Biol, BR-13083970 Campinas, SP, Brazil
[2] Univ Estadual Campinas, Dept Farmacol, Fac Ciencias Med, BR-13083970 Campinas, SP, Brazil
[3] Univ Estadual Campinas, Lab Quim Biol, Inst Quim, BR-13083970 Campinas, SP, Brazil
[4] Univ Mogi Das Cruzes, BR-0870911 Mogi Das Cruzes, SP, Brazil
关键词
dehydrocrotonin; tumour; cytotoxicity; natural killer cell; anti-tumour;
D O I
10.1016/j.ejphar.2004.01.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this work, the anti-tumour properties of dehydrocrotonin and its derivatives were investigated in vitro and in vivo using the Ehrlich ascites tumour model. Treatment of Ehrlich ascites tumour-bearing mice with 20 mg/kg dehydrocrotonin for 4 days significantly increased survival, whereas administration of dehydrocrotonin derivatives was ineffective in affording protection. Compound IV exhibited little activity against Ehrlich tumour cells in vitro. Investigation of the effects of dehydrocrotonin treatment on total natural killer (NK) cell activity of tumour-bearing mice as a possible mechanism of dehydrocrotonin action in vivo revealed that this sesquiterpene lactone significantly improved NK cytotoxicity against YAC-1, a Moloney virus-induced mouse T-cell lymphoma of A/SN origin. As expected, tumour growth in non-treated mice markedly suppressed NK cell cytolysis. No effects on NK functional activity were observed in normal mice receiving dehydrocrotonin. In summary, only the natural compound exhibits anti-tumour efficacy and immunomodulatory actions in vivo, which may be related to its chemical structure. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 50 条
  • [41] Whole cell ELISA for measuring anti-tumour effects of immunotherapies in a mouse tumour model of ALCL
    Carstens, M
    Bittner, C
    Krokowski, M
    Hadlak, M
    Feller, AC
    Merz, H
    IN VIVO, 2003, 17 (04): : 359 - 363
  • [42] SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells
    Viant, Charlotte
    Fenis, Aurore
    Chicanne, Gaetan
    Payrastre, Bernard
    Ugolini, Sophie
    Vivier, Eric
    NATURE COMMUNICATIONS, 2014, 5
  • [43] SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells
    Charlotte Viant
    Aurore Fenis
    Gaëtan Chicanne
    Bernard Payrastre
    Sophie Ugolini
    Eric Vivier
    Nature Communications, 5
  • [44] ANTAGONISM OF ANTI-TUMOUR EFFECTS OF ASPARAGINASE BY METHOTREXATE
    CONNORS, TA
    JONES, M
    BIOCHEMICAL PHARMACOLOGY, 1970, 19 (11) : 2927 - &
  • [45] STRUCTURE AND ACTIVITY RELATIONSHIPS OF PLATINUM COMPLEXES WITH ANTI-TUMOUR ACTIVITY
    BRADDOCK, PD
    CONNORS, TA
    JONES, M
    KHOKHAR, AR
    MELZACK, DH
    TOBE, ML
    CHEMICO-BIOLOGICAL INTERACTIONS, 1975, 11 (03) : 145 - 161
  • [46] ANTI-TUMOUR EFFECTS OF INTERFERON AND ITS POSSIBLE USE AS AN ANTI-NEOPLASTIC AGENT IN MAN
    STRANDER, H
    TEXAS REPORTS ON BIOLOGY AND MEDICINE, 1977, 35 : 429 - 435
  • [47] Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies
    Kendrew, Jane
    Odedra, Rajesh
    Logie, Armelle
    Taylor, Paula J.
    Pearsall, Sharon
    Ogilvie, Donald J.
    Wedge, Stephen R.
    Juergensmeier, Juliane M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1021 - 1032
  • [48] Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma
    Vyth-Dreese, F. A.
    Sein, J.
    van de Kasteele, W.
    Dellemijn, T. A. M.
    van den Bogaard, C.
    Nooijen, W. J.
    de Gast, G. C.
    Haanen, J. B. A. G.
    Bex, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 162 (03): : 447 - 459
  • [49] Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies
    Jane Kendrew
    Rajesh Odedra
    Armelle Logié
    Paula J. Taylor
    Sharon Pearsall
    Donald J. Ogilvie
    Stephen R. Wedge
    Juliane M. Jürgensmeier
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1021 - 1032
  • [50] Anti-tumour activity of bisphosphonates in human myeloma cells
    Shipman, CM
    Rogers, MJ
    Apperley, JF
    Russell, RGG
    Croucher, PI
    LEUKEMIA & LYMPHOMA, 1998, 32 (1-2) : 129 - 138